21:13 , Jul 30, 2019 |  BC Extra  |  Financial News

June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds

Hinova Pharmaceuticals raises $40M series B  Hinova Pharmaceuticals Inc (Chengdu, China) completed a $40 million series B round led by Hermed Capital and Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), with participation from Lang...
23:32 , Apr 30, 2019 |  BC Extra  |  Financial News

April 30 Financial Quick Takes: Mustang, Tot Biopharm, Axcella and more

Mustang raises $27.5M after gene therapy data Mustang Bio Inc. (NASDAQ:MBIO) raised $27.5 million in a follow-on underwritten by Cantor Fitzgerald, Oppenheimer, H.C. Wainwright and Roth Capital. The offering comes on the heels of positive...
21:51 , Feb 22, 2019 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
19:51 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing...
22:57 , Dec 18, 2018 |  BC Extra  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal"...
21:27 , Aug 10, 2018 |  BC Extra  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus...
21:54 , Apr 17, 2018 |  BC Extra  |  Company News

Management tracks: Frequency, AACR, NextCode

Regenerative medicine company Frequency Therapeutics Inc. (Woburn, Mass.) hired William Chin as CMO. He was EVP of scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA) and previously served as executive dean...
20:59 , Oct 20, 2017 |  BioCentury  |  Finance

Stars align for rare AMD

Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use the precision medicine approach that is common to cancer and rare diseases to target mutations in the...
17:34 , Jun 2, 2017 |  BioCentury  |  Emerging Company Profile

Prolonging thrombin production

ApcinteX Ltd. is betting that inhibiting an endogenous brake on thrombin production will generate a therapy for hemophilia A and B that can be used by patients who have developed neutralizing antibodies to factor replacement...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....